Our research focuses on why scar develops in the airway, specifically the larynx and trachea, and developing treatments that may be effective in halting the progression of scar or reversing scar. Airway scar can form both in the hospital setting and in otherwise healthy patients, and we are investigating the causes and risk factors for both subtypes of disease. The research is funded by an NIH R01 and R21 awards from the NIDCD.
Past funding was received from the American College of Surgeons and Triological Society. Dr. Hillel is also a co-investigator on a Multicenter Trial of Treatment Alternatives in Idiopathic Subglottic Stenosis funded by PCORI.
Our research questions include:
Past funding was received from the American College of Surgeons and Triological Society. Dr. Hillel is also a co-investigator on a Multicenter Trial of Treatment Alternatives in Idiopathic Subglottic Stenosis funded by PCORI.
Our research questions include:
What immune cells and inflammatory proteins are critical to the development of laryngotracheal scar?
- What is the role that key immune cells, such as macrophages and T-cells, play in the development of laryngotracheal stenosis?
- How does the presence of bacteria (microbiome) in the larynx and trachea affect the inflammation and scar seen in laryngotracheal stenosis?
- What are the critical pro-inflammatory proteins that lead to increased scar?
- How can we decrease the activity of these cells and proteins to reduce the development of scar?
How can we develop new therapeutics and improve patient outcomes in the management of laryngotracheal scar?
- What are the optimal biomaterials that abrogate fibroproliferation in the airway?
- How can we incorporate drug-depot systems in the airway to reduce the frequency of patient visits to clinic/OR?
How can we improve patient safety by preventing with the development of airway scar in the hospital setting?
- What are risk factors for the development of laryngotracheal stenosis?
- What are effective ways to spread the use of smaller breathing tubes and reduce the length of time they are in place?
- What are effective hospital protocols to identify high-risk patients and strategies to reduce the development of scar?
How can we make current endotracheal and tracheostomy tubes safer for use in patients?
- How can we improve endotracheal tubes and reduce injury to the airway?
- How can we develop drug eluting stents to treat scar?